JSP191 for MDS/AML

Recruiting at 5 trial locations

Overseen by Ankur Varma, MD,PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Jasper Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests JSP191, an antibody that helps clear out diseased blood cells, in adults with MDS or AML who are getting a stem cell transplant. By blocking a critical connection on blood cells, JSP191 makes room for new, healthy stem cells.

Research Team

Lori Muffly, MD,MS

Principal Investigator

Stanford University

Andrew Artz, MD,MS

Principal Investigator

City of Hope Medical Center

Bart Scott, MD

Principal Investigator

Fred Hutchinson Cancer Center

Catherine Lee, MD

Principal Investigator

Huntsman Cancer Institute/ University of Utah

Arpita Gandhi, MD

Principal Investigator

Oregon Health and Science University

Ankur Varma, MD,PhD

Principal Investigator

Rush University Medical Center

Eligibility Criteria

Inclusion Criteria

AML/MDS as defined by specific criteria, including but not limited to the following subtypes: AML in CR, MDS < 5% BM blasts, MDS 5 - 10% BM blasts, AML not in CR or MDS > 10% BM blasts, Patients with human leukocyte antigen (HLA) matched related or unrelated donors, Adequate end organ function as defined in study protocol

Exclusion Criteria

Rewritten Criteria: 1. You currently have an infection that is not being treated or managed properly. 2. You are currently receiving an experimental medication for another study. 3. You have an active cancer that is not a blood cancer. 4. You have had a bone marrow transplant using cells from another person.

Treatment Details

Interventions

• JSP191 (Monoclonal Antibody)

Participant Groups

Group I: Blood Stem Cell Transplant w/ anti-CD117 conditioning Experimental Treatment 1 Intervention

The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.

Who Is Running the Clinical Trial?

Jasper Therapeutics, Inc.

Lead Sponsor

Trials

7

Recruited

310+